Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess in a longitudinal study whether subjective cognitive decline (SCD) and brain β-amyloid (Aβ) contribute unique information to cognitive decline. METHODS: One hundred thirty-six healthy elderly from the Berkeley Aging Cohort Study were followed up for a mean of 4 years. SCD and affective measures were generated from the Geriatric Depression Scale (GDS) with factor analysis on data from a larger set of 347 healthy, nondepressed (GDS <11) elderly individuals. Cognition was summarized with previously validated factor scores. Pittsburgh compound B (PiB)-PET scans were acquired to determine the presence (PiB+) or absence (PiB-) of Aβ pathology. Mixed models were used to assess the independent and interactive effects of SCD, affective features, PiB status, and time on cognition, with adjustment for demographic variables. RESULTS: SCD score demonstrated good construct validity compared to an existing measure of subjective memory and was partially explained by several lower-order measurements. Mixed models revealed that SCD interacted with PiB status to predict change in episodic memory and global cognition over time, with adjustment for affective features. PiB+ individuals with more severe SCD demonstrated the steepest cognitive decline. Worse SCD predicted faster decline in working memory independently of PiB status. No such effects were seen for affective scores when adjusted for SCD. CONCLUSIONS: PiB+ individuals with SCD are at greatest risk of cognitive decline. Evidence for amyloid alone is not sufficient to indicate risk of rapid cognitive decline in healthy elderly. Effects of GDS on cognitive decline in nondepressed cohorts may be driven by SCD rather than subsyndromal depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 1×
“SCD is currently a field of major interest in aging and AD research, but only recently have there been efforts to standardize its measurement.(6) Therefore, previous studies have used a wide range of instruments to characterize SCD, and our study is no different.”
BackgroundRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Self-citationThe Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · cited 5×
“Because clinical trials of Ab-lowering therapies have consistently failed in symptomatic people, several large clinical trials are recruiting cognitively intact people with evidence of brain Ab to treat a preclinical phase of AD.(4) Because this preclinical phase can last decades and clinical trials cannot, there is a…”
BackgroundInfluentialOutcome over seven years of healthy adults with and without subjective cognitive impairment
Reisberg, B., Shulman, M. B., Torossian, C., Leng, L., & Zhu, W. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.10.002 · Cited by 568
Salthouse, T. A. (1994) · Neuropsychology · doi:10.1037/0894-4105.8.4.535 · Cited by 455
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408
Self-citationPerrotin, A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.666 · Cited by 300 · cited 1×
“score, we compared the score to 2 independent subjective memory measurements.(16) The questions were as follows: “How would you rate your memory compared to others your same age?” and “How would you rate your memory compared to yourself 20 years ago?” Participants could rate themselves as better, the same, worse, or m…”
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.9 · Cited by 195
Cited by
The characterisation of subjective cognitive decline
Jessen, F., Amariglio, R. E., Buckley, R. F., van der Flier, W. M., Han, Y., Molinuevo, J. L., Rabin, L., Rentz, D. M., Rodriguez-Gomez, O., Saykin, A. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30368-0 · Cited by 1,389
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives
Ma, L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00009 · Cited by 323
Interventions for subjective cognitive decline: systematic review and meta-analysis
Bhome, R., Berry, A. J., Huntley, J. D., & Howard, R. J. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021610 · Cited by 123
“Research into cerebrospinal fluid (CSF) 15 and neuro-imaging biomarkers 9 10 16 suggest they hold promise for distinguishing between preclinical and non-preclinical AD in patients with SCD but they are not routinely used in clinical practice.”
Background
Metadata
- Authors
- Vogel, J. W., Varga Doležalová, M., La Joie, R., Marks, S. M., Schwimmer, H. D., Landau, S. M., & Jagust, W. J.
- Venue
- Neurology
- Published
- 2017-11-07
- Volume
- 89
- Issue
- 19
- Pages
- 2002-2009
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2763258862
- Cited by
- 71
- References
- 15
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly. https://app.cochat.ai/papers/10.1212/wnl.0000000000004627
- The paper
- Vogel, J. W., Varga Doležalová, M., La Joie, R., Marks, S. M., Schwimmer, H. D., Landau, S. M., & Jagust, W. J. (2017). Subjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly. Neurology. https://doi.org/10.1212/wnl.0000000000004627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.